NRL-1045 (VAL-1045)
Neurological disorder (undisclosed)
Pre-clinical/Phase 1Active
Key Facts
About Neurelis
Neurelis is a private, commercial-stage biopharmaceutical company specializing in neurology, with a core focus on epilepsy. The company has built its portfolio around proprietary drug delivery enhancement technologies—Intravail®, ProTek®, and Hydrogel™—which enable non-invasive administration of therapeutics. Its lead commercial product is Valtoco® (diazepam nasal spray) for acute treatment of seizure clusters, and it maintains a pipeline of investigational neurology candidates. Neurelis operates with a patient-centric model, offering savings and support programs to ensure access to its therapies.
View full company profile